Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2026 Results: August 7, 2025

BOSTON, July 9, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, August 7, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on August 7, 2025.

The call can be accessed via teleconference at: Q1 2026 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.

A live webcast of the call can be accessed on Haemonetics' investor relations website. Webcast Link: https://edge.media-server.com/mmc/p/wv7zkgdh 

A replay of the conference call and webcast will be available for one year beginning on August 7, 2025 at 11:00 am ET using the conference call webcast link provided in this press release.

ABOUT HAEMONETICS

Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit www.haemonetics.com.

Investor Contacts:

Olga Guyette, Vice President-Investor Relations & Treasury     

(781) 356-9763 

[email protected]       

David Trenk, Manager-Investor Relations

(203) 733-4987 

[email protected]                                                                                

Media Contact:   

Josh Gitelson, Sr. Director-Global Communications   

(781) 356-9776

[email protected] 

SOURCE Haemonetics Corporation